ISN Webinar: How GLP1 receptor agonist evolved from weight management drugs to kidney protective therapy?

This webinar aims to review both experimental studies and clinical trials that examined the efficacy of GLP-1 receptor agonists in mitigating the progression of DKD. Attendees will gain insights into the mechanisms of which GLP-1 receptor agonists exert renoprotective effects. The session will review the clinical practice guidelines, offering practical guidance and discussions on combination therapies, and how to incorporate GLP-1 receptor agonists into current guidelines-directed medical therapies for type 2 diabetic patients with and without CKD. 

Learning objectives:

- Understand how GLP-1 receptor agonists impact kidney health through mechanisms such as improved glycemic control, reduction of oxidative stress, blood pressure regulation, and modulation of inflammatory pathways. 
- Review the latest trial evidence of GLP-1 receptor agonists in the management of DKD.
- Discuss combination therapies in DKD and provide practice guidance on how to integrate GLP-1 receptor agonists into current treatment protocols in type 2 diabetes and CKD. 

Further reading:

- ISN Webinar: Unraveling the biology of GLP1-receptor agonist for obesity management and metabolic control in CKD

 This webinar is supported by Novo Nordisk.